205 related articles for article (PubMed ID: 6937954)
1. Comparative in vivo efficiency of cefamandole and cefoxitin against Bacteroides fragilis.
Bergeron MG; Gauvreau L; Nguyen BM
Scand J Infect Dis Suppl; 1980; suppl 25():60-5. PubMed ID: 6937954
[TBL] [Abstract][Full Text] [Related]
2. Serum and tissue concentrations of cefoxitin and cefamandole in women undergoing hysterectomy.
French MA; Quintiliani R; Nightingale CH; Russo JN
Obstet Gynecol; 1983 Jan; 61(1):42-7. PubMed ID: 6823348
[TBL] [Abstract][Full Text] [Related]
3. beta-lactamases in bacteroides.
Nord CE; Olsson B; Dornbusch K
Scand J Infect Dis Suppl; 1978; (13):27-32. PubMed ID: 28561
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
Brook I
J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
[TBL] [Abstract][Full Text] [Related]
5. Bacteroides fragilis septicemia during cefamandole therapy.
Righter J
Can Med Assoc J; 1981 Sep; 125(5):422, 424. PubMed ID: 7284925
[No Abstract] [Full Text] [Related]
6. Studies with cefuroxime and cefoxitin.
Geddes AM; McGhie D; Ball AP; Gould I
Scand J Infect Dis Suppl; 1978; (13):78-81. PubMed ID: 308260
[TBL] [Abstract][Full Text] [Related]
7. Cefamandole against Bacteroides fragilis.
McAllister TA
Scand J Infect Dis Suppl; 1980; suppl 25():32-6. PubMed ID: 6937949
[TBL] [Abstract][Full Text] [Related]
8. Penetration of cephalothin and cefoxitin into experimental infections with Bacteroides fragilis.
O'Keefe JP; Tally FP; Barza M; Gorbach SL
Rev Infect Dis; 1979; 1(1):106-12. PubMed ID: 318211
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cefoxitin and cephalothin therapy of a mixed Bacteroides fragilis and Fusobacterius necrophorum infection in mice.
Hackman AS; Wilkins TD
Antimicrob Agents Chemother; 1975 Aug; 8(2):224-5. PubMed ID: 1180547
[TBL] [Abstract][Full Text] [Related]
10. The role of beta-lactamase and the permeability barrier on the activity of cephalosporins against members of the Bacteroides fragilis group.
Malouin F; Lamothe F
Can J Microbiol; 1987 Mar; 33(3):262-6. PubMed ID: 3105858
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of Bacteroides species to modern antimicrobial preparations.
Závadová M; Tynková S; Adensámová J; Brezinová L
J Hyg Epidemiol Microbiol Immunol; 1983; 27(1):51-9. PubMed ID: 6602163
[TBL] [Abstract][Full Text] [Related]
12. Intraocular levels of cefamandole compared with cefazolin after subconjunctival injection in rabbits.
Barza M; Kane A; Baum JL
Invest Ophthalmol Vis Sci; 1979 Mar; 18(3):250-5. PubMed ID: 311356
[TBL] [Abstract][Full Text] [Related]
13. Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates.
Bieluch VM; Cuchural GJ; Snydman DR; Gorbach SL; Tally FP
Diagn Microbiol Infect Dis; 1987 Jun; 7(2):119-26. PubMed ID: 3652652
[TBL] [Abstract][Full Text] [Related]
14. Cefamandole therapy of endomyometritis following cesarean section.
Gibbs RS; Huff RW
Am J Obstet Gynecol; 1980 Jan; 136(1):32-7. PubMed ID: 7352484
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of two beta-lactam antibiotics against strains of the Bacteroides fragilis group isolated from humans and from Callithrix penicillata marmosets.
Avila-Campos MJ; de Carvalho MA; Veiga-Damasceno CA; Osório-Cisalpino E
Rev Latinoam Microbiol; 1994; 36(3):159-62. PubMed ID: 7709091
[TBL] [Abstract][Full Text] [Related]
16. Penetration of cefamandole, cephalothin, and desacetylcephalothin into fibrin clots.
Bergeron MG; Nguyen BM; Trottier S; Gauvreau L
Antimicrob Agents Chemother; 1977 Dec; 12(6):682-7. PubMed ID: 931366
[TBL] [Abstract][Full Text] [Related]
17. Drug therapy reviews: antimicrobial spectrum, pharmacology and therapeutic use of cefamandole and cefoxitin.
Fraser DG
Am J Hosp Pharm; 1979 Nov; 36(11):1503-8. PubMed ID: 391032
[No Abstract] [Full Text] [Related]
18. A decisive period in cefoxitin prophylaxis of experimental synergistic wound infection produced by Bacteroides fragilis and Escherichia coli.
Shapiro M; Sacks T
Isr J Med Sci; 1982 Aug; 18(8):863-5. PubMed ID: 6749759
[TBL] [Abstract][Full Text] [Related]
19. [In vitro activity of cefotaxime on anaerobes (author's transl)].
Soussy CJ; Thibault M; Duval J
Nouv Presse Med; 1981 Feb; 10(8):556-8. PubMed ID: 6259592
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of moxalactam in an animal model of subcutaneous abscesses: penetration into infected sites and in vivo activity against Bacteroides fragilis.
Bartlett JG; Joiner KA; Dezfulian M; Marien GJ
Rev Infect Dis; 1982; 4 Suppl():S664-9. PubMed ID: 6218580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
